← All trials
NCT02234739
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Oct 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Red Cross Hospital, Hangzhou, ChinaLead sponsor
- First People's Hospital of HangzhouCollaborator
- Hangzhou Red Cross HospitalOverall official - principal investigator
- Red Cross Hospital, Hangzhou, ChinaReponsible party - principal investigator
- Second People's Hospital of HangzhouCollaborator
- Hangzhou Hospital of Traditional Chinese MedicineCollaborator
- Xiaoshan People's HospitalCollaborator
- Huzhou UniversityCollaborator
- Ningbo No. 5 HospitalCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.